Skip to content
NOWCAST WLKY News at Noon
Watch on Demand
Advertisement

After a year of turmoil, cancer researchers see promising signs for mRNA vaccines

After a year of turmoil, cancer researchers see promising signs for mRNA vaccines
Pancreatic cancer is one of the deadliest types of cancers. Survival rates are low because it's very hard to detect in its early stages. Now, Jupiter Medical Center is performing what they call a life saving procedure, hoping to provide the best possible outcomes for patients. Let's go on the record from Wpbf 25. This is on the record with Natalie Pozo. Welcome on this Morning. We're talking about pancreatic cancer and the advances being made in the field. This morning we have Doctor Chanel bag wenton from Jupiter Medical Center to talk more about this. Doctor, you are the very long titles here. Medical director of gastrointestinal surgical oncology program. And also the program director of the National Pancreas Foundation Pancreatic Cancer Center program. So you have a lot of experience and in this field. So first let's talk a little bit about how does pancreatic cancer form. Yeah. Thank you for having me. First of all I mean this is a very interesting diagnosis in terms of how we're learning about it, and especially with regards to being commonly a disease of older age. Pancreas cancer really refers to, the, change in the cells within the pancreas that primarily function to help with how the pancreas can digest a lot of the foods that we eat. A lot of people know the pancreas serves to function with regards to insulin production and diabetes. So there are different types of pancreatic cancer, but the one that we fear most is known as pancreatic ductal adenocarcinoma, which specifically refers to some sort of derangement in those cells where they can detect or develop a mutation and over time develop into pancreas cancer. And unfortunately, you don't really start to feel symptoms until you're later on. A different stage of the cancer. Yeah. That is the aggressive nature of this disease. Is that especially as it gets diagnosed, sometimes it can be invisible to the body, where it can hide. And as a result of that, it can grow unchecked. And usually once patients start to develop symptoms back pain, loss of appetite, even jaundice, yellowing of the eyes and skin, those are symptoms that sometimes present at a much later stage where we find it, and that survival usually mirrors that in terms of being a lot poorer when it's detected late. Is there anything that people can do to prevent this? Can they do any sort of tests? Yeah. So there are as far as just talking about the day to day changes that we can all do in terms of, of, of our overall cancer care. Smoking is the most common modifiable risk factor with pancreatic cancer. Having, well-balanced diet, high in fruits, vegetables, less, fatty foods, red meat, things like that. Similarly, we're seeing a trend where there's an increase in pancreas cancer secondary to the increase in obesity and diabetes, particularly among younger patients. So as a result of that, we are seeing that trend in terms of increase. But going back to your point about earlier tests of screening, that is one of the advancements that we are, you know, seeing a push in that direction where, this is a diagnosis that we don't have a clear cut way to detect it before it becomes pancreas cancer. But there are earlier blood tests and, what we call liquid biopsies or cancer screening that, can be performed with higher sensitivity and specificity for this type of cancer that can be detected at earlier stages before patients start to develop those symptoms. I was telling you that unfortunately, my father in law died, of pancreatic cancer. Is this something that runs in the family? It absolutely can. We do see a genetic predisposition somewhere between 10 to 12%, depending on the type of cancer. But that is a known risk factor with regards to pancreas cancer. So much so that we do encourage and that our center, recommend genetic counseling for all patients just to see if there is, in fact, a genetic predisposition that would allow us to learn about that cancer, but also potentially even treat additional cancers that they may be at risk for. And we're going to talk a little bit about that a little bit later on in the show. So talk to me about this, procedure at Jupiter Medical Center that you guys are doing that. That's really just giving a lot of hope to to patients. Yeah. So this is what's known as, robotic Whipple. It specifically refers to an operation where you're removing the head of the pancreas. The pancreas is an organ that's deeply nestled towards the back of the body, but it's almost at the crossroads of very critical blood vessels. It oftentimes requires you to remove the head of the pancreas, the intestine, the bile duct, multiple organs to do a very complex reconstruction for cancers in that area. We are talking about the precision of millimeters, where changes in technique can absolutely lend themselves to different outcomes, as well as, patients being able to have surgery because the majority of the time patients are not candidates for surgery. Over the past year, we've been able to utilize a robotic approach to treat cancers in that location. And what we've demonstrated is that patients have been able to have a faster recovery back to their functional baseline, less pain, increased sort of organ, function after surgery and where that translates, particularly with patients dealing with cancer, is that they can get back to their treatment a lot earlier. And who qualifies for this kind of, procedure? You know, patient selection is key. A lot of it with regards to the decision making is largely based on experience. So it's not so much about, you know, doing the most volume, but a lot of it is really just the understanding with the patient to know that this could translate to faster outcomes. And with that, back to living normally, but going back to the decision making in terms of patient selection, the majority of patients with a pancreas cancer, as long as they don't have the specific blood vessel involvement where we may need to do a blood vessel reconstruction, if they have a mass that would allow for them, especially with regards to the robotic surgery and using small incisions to approach the pancreas, is that we want to make sure that we're approaching it in a very safe, meticulous way so that we can be precise with the dissection. So if someone is diagnosed with with stage four pancreatic cancer, could they possibly be a candidate for this? Yeah. Stage four unfortunately, isn't a candidate for pancreas cancer. Thank you for making that distinction. Is that the majority of our patients have cancer that's localized to the pancreas or the nearby lymph node, certainly with involvement of those blood vessels around the pancreas, we can approach that surgery in a way to resect and or do a surgery to remove and reconstruct the blood vessels. But once a cancer has metastasized or spread, which implies stage four, it's less likely that surgery is going to be of benefit. Even if, let's say, the theoretical disease that has metastasized could have a surgery to remove it there. Usually that doesn't track to the improved survival that we want with this disease because of how aggressive it is. All right, Doctor Penguin, a thank you so much for being here with us this morning. And talk to us about this. Just very, very important topic here. Coming up, we're going to sit down with a pancreatic cancer patient and her journey since being diagnosed. You're watching on the record. On Wpbf 25. We continue our conversation this morning on pancreatic cancer. Nicole Locher is a pancreatic cancer patient here to share her story to raise awareness. Thanks so much for being here with us, Nicole. So happy to see you. Talk to us about just the day you were told that you had pancreatic cancer. It was a call it 3:00 in the afternoon, and it was, the gastroenterologist that had done the biopsy, because they had seen on MRI that there was a mass, and he just said, you know, this is a dental carcinoma. And you need to see a, an oncologist immediately. He had a referral for me. I was in the oncologist office on Friday. Well, I had my port put in the following Wednesday. Started chemo the Tuesday after that. And it was my oncologist that recommended Doctor Bhagwan. And, he also gave me other options, like Mayo Clinic, Miami, Moffitt Center. But he was very, very confident that the right choice would be doctor. But London, especially because he was local. Yeah, absolutely. So yeah. And and we were talking about the procedure they have at Jupiter Medical Center. I know you had a different procedure done than what we were speaking about with the doctor. Can you tell us about that? It it was, I would say similar to having my gallbladder removed. So it was all laparoscopic. So I had a few incisions and then after surgery, I did have a drain. That I had to take care of for a couple weeks with the help of home care, but I would say probably four days, five days after surgery, I was up and about and able to do most everything that that I was approved to do. I mean, you seem like such a strong, strong woman. You what? Just kind of went through your mind when when you were told about that diagnosis? I immediately, of course, thought of Alex Trebek and, you know, Patrick Swayze in the, you know, the ones that you hear about that are diagnosed at stage four. So I was I was very scared. But once I met with my medical oncologist and then doctor began and, I had a lot of hope and just figured, all right, let's go. Yeah. Were you feeling any symptoms? What made you want to go to the doctor? So I in late April, I had, lower quadrant pain on my right. And it kept getting it kept getting worse and worse. It took about two weeks, and I finally went to the doctor, and they, are to the emergency room, and they did a CT, and thought it was pancreatitis. It matched with my blood work. But after discharge, I was I was inpatient for a few days, and after discharge, I still didn't feel right. So I scheduled a follow up with a gastroenterologist, and she, took me very seriously, which I appreciated. Oh, goodness, you did that. You trusted your miss your instincts and wanting to make that appointment. Yeah. And she she started with, some imaging that had contrast in it. She said it would help see better and some cancer blood markers and and she that's a procedure. We went down and got the official diagnosis. So it took, I'd say about a month with all the diagnostics and waiting on the age where you diagnosed with, to be, I believe. Okay. Yeah. Yeah. I mean, when you heard two, though, that must have caused a little bit of relief. Yes, yes, absolutely, absolutely. And I've had an amazing support system. My medical team is incredible. You know, I couldn't have more confidence in them. I also see someone behind the camera here who seems like it's an incredible support system to you. Yes. That is John, and it's my significant other. It's that John was giving you a big hug right before you came out here. Yeah, I saw that. That was very, very sweet. John. Nicole, what would you say to people who are in a similar situation to you, you know, who maybe have just been diagnosed, or maybe to a family member who has a loved one that has been diagnosed to advocate for yourself. It's like if you feel like something's wrong, go with it. You know? And if if someone tells you that, yeah, let's not try again, you know, or if the treatment that, that they tried is, you know, isn't making you feel better, talk to them. It's scary, but. And it changes a lot. It does, you know, like I haven't I've been out of work now for a while. But just, you know, try to keep on living your life. Well, yeah. We. When my first with my first round of chemo, we went to, North Carolina to see Pearl jam and to Missouri, Saint Augustine, you know, we we tried to get out when we could. Yeah. So, and how does your recovery look? From now on. What is your what a doctor's telling you? That as of right now, I'm cancer free. Thank you. I started my second half of chemo yesterday. Which is why I have my pump. And then after, I think five rounds of that, then I'll meet with a radiation oncologist. Well, I know you said that. Then things obviously change for you and and that you're out of work right now. But you're here with us. Yes. And that's the most important thing. Yes, absolutely. Well, for sharing your story with us. Thank you. Next, we're going to learn more about genetic testing and how it can help identify people at an elevated risk for cancer. Welcome back. Connie Murphy is a board certified nurse practitioner who is a certified in cancer genetics risk testing, risk assessment, testing. At Jupiter Medical Center. Connie, thanks so much for being here with us this morning. We spoke with Doctor Bandwidth earlier on in the show, and he was mentioning how we're seeing an increased risk in pancreatic cancer. Cancer and also younger patients. Yes, absolutely. There are about 646,000 cases diagnosed last year. Some of it is attributed to attributed to their lifestyle, smoking, obesity. As Doctor Greg London was referring to alcohol use. But we do see a definite increase in the incidence. And why do you think we're seeing it now in younger patients as well? That's an unknown. I you know, we do talk about cancer, genetic testing for hereditary cancer syndromes, meaning that someone has inherited a faulty gene from a parent that can elevate their risk for cancers, including pancreatic cancer. And those are the patients we want to find early, because we do have screening tools now that we can use to detect their pancreas cancer. So what kind of screening tools do you have? And is it for all sorts of cancers that are specific kinds of cancer? Well, that's the piece about genetic testing. When we identify a family or a person who is at risk for cancers, and every gene that we test, we do panels of 40 to 77 genes, routinely. So when we identify someone who has a faulty gene that elevates their risk, each of these genes is associated with a different type of cancer and with a different level of risk. So there is a lot of crossover among the genes. Our goal is once we've identified these families as to offer them high risk surveillance, to offer them risk reducing medications, risk reducing surgery, and certainly talk about lifestyle modifications. So that's big to to mitigate the risk. I was, telling a doctor bang one death about my my father in law, he passed away from pancreatic cancer. So should my husband. Should his siblings be doing these kinds of testing? Should I do this on my children as well? So absolutely, any person diagnosed with pancreatic cancer should be offered genetic testing early on because it can inform their planning, their treatment planning the medications that we use. And then once we've identified a person with a faulty gene, all of their biologic relatives need testing. So my role isn't just about patient. It becomes the family. And the current guidelines say that if the person with pancreatic cancer was not offered genetic testing because there aren't programs like ours at Jupiter Medical Center or every cancer center, I think that's the case with my father in law. I don't think he was ever offered that. Yeah, and that saddens me because it is a national guideline. It is it is a societal guideline. It is a gold standard to get them and then get them tested right away. And then we move on to testing their family members all first degree relatives, that sibling or child of your father in law should be offered appropriate genetic counseling and test. What if he didn't have that test on? Is there still something you can do for, let's say, my husband and his siblings? Oh, that's absolutely. Well, okay. Yeah. If the person that was affected did not have genetic testing, then we move on to their site. Their children and your and their children. If someone is positive, then they can pass on the genetic defect. So anyone who is positive their children should be age appropriately tested. And what does this test look like? It's it's actually it's just a blood test. Okay. I use blood almost exclusively because we can then analyze DNA and RNA, which has a bigger yield, for these genetic variants that increase cancer risk. We we spent about an hour with our patient discussing what we're going to do. Potential results. Positive, negative, uncertain. It's very important for patients to understand they can have an uncertain result, where we find a variation on a gene that we don't understand yet and we don't act on it. And that is something they have to get their head around, because that can be anxiety producing. Connie, do you have a story that sticks out to you? From a patient or from a family member of the patient? I have, yes, I have a I'm sure you have so many I do. I have several families that, I've become very close with over the years because one of the things we offer in our program is high risk surveillance. So we don't just test you, tell you you're positive and send you on your way. You know, we're going to develop an individualized care plan, and we have the benefit of an EMR electronic medical record called my Gene Council through the courtesy of a generous donor that provided us with that which provides our patients and their families with a living lab report. That means any time there's an update about their gene, about their cancer risks, about how we provide them surveillance, about what surgeries we do, they get an email. It's a lot faster than me trying to keep up with my 3000 patients. Right. So they're offered an email. And so that's something that makes us unique. I have families that come in like sisters will come together. Mothers, daughters, fathers. You know, men are included in this. It's it's everybody inherits a gene from your parents. So if you have a parent with a faulty gene, male or female, you should undergo genetic counseling. Okay? So people that want to do this, what do we want to tell them? If you have a strong family history of cancer or if you've been diagnosed with cancer yourself, at our center, we actually take every prospective cancer case and and have a tumor conference where we discuss the case and the care, and I'm there, or my genetic counselor associate Robin Urban, is there to tell the our team who meets criteria for testing. And so if you have a strong family history of cancer, you want to talk with your health care provider to see if it's compelling enough to warrant genetic testing. All right, Connie, anything else you want to add before we wrap up? I think it's really important for people to be aware we've moved way beyond BRCA one and BRCA two genes. There are multiple cancer genes out there that if those genes are faulty, we're at risk. We need to know our family history. That's ideal. Absolutely. I mean there's been to so many advances also just in medicine. I'm going to take advantage of that. Right. All right. Thank you so much. We'll be right back. Thank you for making us a part of your morning. As always, we encourage you to be part of our discussion each and every Sunday, right here at 10 a.m.. Until then, you can watch this morning's on the Record and every episode on our website, wpbf.com, and our free Wpbf 25 news app. Have a wonderful Sunday. We'll see you again next weekend. For.
CNN logo
Updated: 9:20 AM EDT Apr 20, 2026
Editorial Standards
Advertisement
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines
CNN logo
Updated: 9:20 AM EDT Apr 20, 2026
Editorial Standards
Vita Sara Blechner’s life changed on a Saturday afternoon. The middle school librarian was home in Oceanside, New York, when she felt shooting pains in her back. After an acid reflux pill couldn’t soothe the fiery feeling, her husband suggested a trip to the emergency room.It was March 7, 2020, just days before COVID-19 would turn New York City’s hospitals into something approaching a war zone. If the doctors knew what was coming, they didn’t let on. They were cool and collected as they put Blechner, then 67, through a sonogram and a CT scan. But the pictures turned her world upside down.“They said I have a tumor on my pancreas. And I said, ‘No, it can’t be. This can’t be happening to me. I don’t drink. I don’t smoke. I’m leading a healthy life.’”After an anxious two days in the hospital, Blechner headed home and weighed her options. There weren’t many. Pancreatic cancer is notoriously unforgiving: Just 1 in 4 patients lives a year after their diagnosis. Just 1 in 10 makes it two years.Blechner felt the numbers in the pit of her stomach as she, her husband and their three adult sons made calls and pored over the internet, deciding her next move. They settled on a path that would land Blechner in a fast-moving and often misunderstood realm of cancer research.Messenger RNA, or mRNA, is a single-stranded molecule that delivers genetic information from DNA to direct the formation of proteins. It’s known to most people from high school science classes or for its use in COVID vaccines. But long before anyone had heard of COVID, mRNA was generating intense excitement in the cancer research community. BioNTech, the German company that designed the COVID vaccine for Pfizer, adapted that vaccine from a platform it had been using to develop cancer treatments for nearly a decade.The mRNA-based COVID vaccines produced by Pfizer and Moderna helped blunt the impact of the pandemic but also sparked political backlash that, in the past year, has threatened to slow or derail dozens of potential cancer treatments. Now, after a tumultuous 12 months, there are signs that the mRNA train is still on track.“It’s exciting,” said Elizabeth Jaffee, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. “There’s been a number of successes in early-stage, positive trials.”Dr. Catherine Wu, a professor of medicine at Dana Farber Cancer Institute and Harvard Medical School, says the recent stretch of positive real-world results helped drive the recent announcement by the National Cancer Institute that it would help raise $200 million specifically for novel cancer vaccines.“We’re getting a lot of support from NCI in terms of developing and promoting cancer vaccines, and mRNA vaccines are a major part of that portfolio,” she said.An unforgiving enemyTo guide her treatment, Blechner turned to doctors at Memorial Sloan Kettering Cancer Center, including Dr. Vinod Balachandran, director of MSK’s Olayan Center for Cancer Vaccines.It’s more challenging to make a vaccine against cancer than it is to create a vaccine against a virus or bacteria, Balachandran says. “That’s because our body’s immune systems are hard-wired to recognize viruses and pathogens as foreign, so a vaccine is teaching our body to do something it already wants to do. In contrast, cancer is ourselves. It’s derived from our own tissues.”Much of Balachandran’s work the past two decades has focused on pancreatic tumors because the disease is such a tough nut to crack. “It’s a cancer where nothing had really worked,” he said.When Blechner arrived at MSK, he was just launching a trial of an experimental mRNA-based vaccine against pancreatic cancer, in combination with standard immunotherapy and chemotherapy. He felt like a successful vaccine would also have the potential for wider application. “If we could break through and crack the toughest one, it could unlock how to crack the other , because it would provide a blueprint.”To develop the vaccine, he began by studying “super-survivors”: the fewer than 10% of pancreatic cancer patients who live more than five years from the time of diagnosis. He found that their immune systems were especially good at spontaneously recognizing cancer cells as foreign. In fact, Balachandran says, these patients had about 12 times as many T-cells - a specialized type of immune cell - inside their tumors as average patients. The same T cells were circulating for more than a decade, in some cases.Balachandran also realized that these weren’t generic cancer-fighters. “These T cells were recognizing mutations,” he said, “but each person’s immune system was recognizing their cancer as foreign in a very specific way. To replicate this would require us to teach each individual person’s immune system how to recognize their individual cancer. It would be an individualized vaccine. And we felt the best technology for rapid custom cancer vaccination was to use RNA.”Taking a chance as a research volunteerAfter Blechner signed on for the trial, the first step was surgery. She underwent what’s known as a Whipple procedure to remove the tumor in the head of her pancreas. In a lab at MSK, the tumor was preserved and sliced into fine pieces, each thinner than a human hair. In less than 72 hours, the package was en route to Germany, where technicians at BioNTech took steps to process the material into a clear liquid: a personalized vaccine, custom-made for Vita Sara Blechner.A little more than two months after her diagnosis, the vaccine concoction from Germany arrived back in New York. By that time, she had been given a dose of an immune checkpoint inhibitor, an immunotherapy drug designed to make her immune cells more effective in fighting cancer. For weekly infusions of the vaccine, her husband, Simon, would drive Blechner from Oceanside to the MSK hospital on Manhattan’s East Side. It was the height of the COVID pandemic, so instead of running errands or visiting friends after dropping her off, he would drive through empty streets and wait back home on Long Island. Blechner would lie in a hospital bed for eight hours while the vaccine coursed through her body, until Simon returned to pick her up.After nine weeks, she was done and ready for the next step in her treatment: chemotherapy. But chemo was a fiasco. Blechner suffered mightily, with side effects so severe that doctors had to halt treatment. “I got very sick,” she recalled.“I only had three sessions before they had to stop, and I was in and out of the hospital three or four times. I was down to 90 pounds. I had no appetite. I was constantly nauseous, and my liver was damaged,” she said. “My doctor said to me she never thought she’d see me again.”By the time she felt strong enough to try again, her doctors felt it would be unsafe to resume. She hoped that stopping early wouldn’t make a difference. But she would have to wait and see.She tells this story more than six years later: Blechner not only survived longer than anyone expected, she’s still doing well and showing no sign of cancer.And she’s no singular exception. Of 16 patients in Balachandran’s trial, eight showed a dramatic immune response to the mRNA-based vaccine. Seven of the eight are alive and well six years after the trial began, a finding that was to be presented Monday at the American Association of Cancer Research meeting in San Diego.“It’s exciting,” Balachandran said. “The implication is that you can make a very strong immune response against the toughest of cancers, and it can last for this long. So if you could do it here, you could potentially do it in many other cancers.”Although a study with 16 patients is far from definitive, a larger multisite trial has been underway for a year.The announcement comes on the heels of other encouraging news for pancreatic cancer patients. Earlier this month, the New York Times published an interview with former U.S. Sen. Ben Sasse of Nebraska, who has been battling advanced pancreatic cancer and told the Times he’s been taking an experimental drug that caused his tumors to shrink, albeit with some painful side effects. Last week, Revolution Medicines, the California-based biotech company running the phase 3 trial that Sasse is part of, said in a news release that for patients whose cancer had spread, the drug nearly doubled survival time to 13.2 months, compared with 6.7 months among participants who didn’t get the drug. Revolution also said it will seek approval from the U.S. Food and Drug Administration for the drug, called daraxonrasib.A promising technology under fireAlthough much smaller than the Revolution study, the MSK trial stands as proof of concept for the promise of mRNA-based vaccines. The field has been a source of great excitement in recent years. But it also faced backlash in the wake of the pandemic and public concerns over COVID vaccines, even as most experts say major safety concerns around the latter are unfounded.For cancer researchers, an early warning sign appeared in March 2025, when scientists reported that the acting director of the National Institutes of Health, Dr. Matthew Memoli, had sent a letter asking that all grants, collaborations or contracts involving mRNA be flagged.For some, the low point came in May, when the White House proposed an unprecedented cut of more than 40% to funding for the National Cancer Institute. Twenty-six days later, in an apparently unrelated move, the U.S. Department of Health and Human Services canceled a $590 million deal with Moderna to develop an mRNA-based vaccine against emerging pandemic influenza. In August, HHS followed up by announcing it would no longer fund mRNA research through the Biomedical Advanced Research and Development Authority. The latter move involved the cancellation of 22 separate contracts.More recently, the FDA canceled its review of Moderna’s mRNA-based flu vaccine, while criticizing the design of the company’s clinical trial, but the agency reversed its decision a week later after fierce criticism.FDA Commissioner Dr. Marty Makary has said the agency bears no animus toward mRNA and that it terminated contracts last year solely to save taxpayer money. “The companies that made mRNA vaccines made over $50 billion. They can fund their own research,” Makary said at a news conference in February.Still, many researchers who once saw a bright future felt their faith shaken. “The external threats are real,” Wu said. “It forced us to really step back and think. I wouldn’t be genuine if I said we weren’t all concerned.”Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute, says mistrust of mRNA vaccines since the pandemic has at times made it harder to recruit people into his clinical trials.“Most people don’t have significant concerns, but some are reluctant,” Sullivan said. “The skepticism over vaccines in general is a little bit lessened around cancer vaccines, but not totally, and some people are resistant to the concept, even when they’re fighting cancer.”One technology, many pathsSullivan is an investigator on multiple studies with mRNA vaccines, including a large-scale trial run by drugmakers Moderna and Merck, testing an mRNA-based therapy in combination with Keytruda, an immunotherapy drug, as a treatment for melanoma. In January, the companies announced that the combination cut the death rate for participants in their study by 49% over five years. A larger phase 3 trial is underway, and the companies are also testing the therapy against non-small cell lung cancer, bladder cancer and renal cell carcinoma.Like the vaccine that helped Blechner, Merck and Moderna’s melanoma treatment is personalized, meaning an individual patient’s tumor cells are used to engineer a highly specific immune response. Another approach involves what are called generalized or off-the-shelf vaccines, that are not tailored to each individual patient. BioNTech and the Moderna/Merck collaboration are both working on approaches that use mRNA to encode and deliver a predefined set of antigens - immune targets - that are typically shared across patients with a given tumor type in hopes of stimulating the immune system into a more aggressive response.Dr. Elias Sayour, a pediatric oncologist and researcher at the University of Florida, has gone a step further in the “generic” direction, testing mRNA vaccines that don’t code for any specific antigen at all. In a study published last year in the journal Nature Biomedical Engineering, Sayour treated mice with a generalized vaccine, using mRNA to stimulate production of a protein called PD-L1, making their tumors more susceptible to immunotherapy. It worked.“We’ve discovered that mRNA doesn’t need to be specific, to reprogram the immune response,” Sayour said.“We’re trying to create a new paradigm,” he added. “It takes weeks to create a personalized vaccine. The idea of universalization is to wake up the immune system more rapidly.”He says the two approaches could, in theory, complement each other: A newly diagnosed patient might receive an off-the-shelf vaccine to ramp up their immune system and a personalized vaccine later in their course of treatment.A recent illustration of the “universal vaccine” approach came in a study led by Drs. Adam Grippin and Steven Lin of MD Anderson Cancer Center. They reviewed records of more than a thousand cancer patients treated with immune checkpoint inhibitors and found that getting an mRNA-based COVID vaccine was linked to a significantly better response to cancer drugs.Patients with small cell lung cancer who had gotten a COVID shot within 100 days of starting treatment lived nearly twice as long as those who hadn’t. For those with melanoma, researchers couldn’t calculate the difference in survival time because so many of the patients who had gotten a COVID vaccine were still alive.“Most people think about vaccines as a laser-guided missile,” said Grippin, who before coming to MD Anderson was a graduate student in Sayour’s lab. “That may be true, but our research suggests that mRNA also acts as a siren call to the overall immune system.”Grippin is now collaborating with Sayour to plan a trial in which patients will be intentionally given a COVID vaccine prior to starting cancer treatment.Money flowing but still tightDr. Robert Vonderheide, director of the Abramson Cancer Center at the University of Pennsylvania and president-elect of the American Association for Cancer Research, says that the field took hits last year but that public pressure turned the tide. “The entire country has been asking, ‘How valuable is cancer research to our society?’ And what we heard from the public and our patients is, it’s super-important.”Federal research grants have started to flow again, after major interruptions over the past several months. Last week, NCI Director Anthony Letai told the Cancer Letter podcast that 22 competitive grants were awarded March 17 and another 167 awarded over the next three-plus weeks.Still, there are scars. One of Sayour’s proposals – to test an mRNA-based vaccine against a rare form of childhood brain tumor – was approved by the NCI last year. But after the agency reduced by nearly half its total number of awards, he says the money never arrived.He says he expects the work to go forward, eventually, but it will take time to find the funding. “As you can imagine, I’ve shifted my approach to finances,” Sayour said. “The reality is, there’s a lot of dependency on the federal government, and if you put all your faith in one stock, you could go under pretty quickly.”While federal funding remains tight, the most prominent mRNA cancer vaccines have attracted industry support and are not reliant on grants. Moderna says it expects to release data from the phase 3 melanoma trial this year. Genentech and BioNTech are sponsoring the global multisite test of the vaccine that Blechner received, with Balachandran leading efforts at MSK.“You need a platform that is fast and potent, flexible and scalable,” Balachandran said. “There are other ways to generate immune responses, but the RNA platform at the moment seems to be superior.”Although none of the cancer vaccine platforms has inspired major safety concerns, Jaffee notes that thanks to the COVID experience, mRNA vaccines have a particularly extensive record. “We’ve seen two-billion-plus injections, and there’s no data to show that mRNA vaccines cause any serious problems,” she said.Vita Sara Blechner is no longer waiting for the other shoe to drop. “I guess once I hit my fifth year , it really sank in that I’m doing well. I said, ‘I beat the odds.’ Now I’m grateful every day,” she said. “I’m really looking forward to my sons getting married. I’m looking forward to the holidays, since I have the strength to do the work and have everyone over. We just had a family event a week ago, and we danced and ate and had a great time. Every day is wonderful.”

Vita Sara Blechner’s life changed on a Saturday afternoon. The middle school librarian was home in Oceanside, New York, when she felt shooting pains in her back. After an acid reflux pill couldn’t soothe the fiery feeling, her husband suggested a trip to the emergency room.

It was March 7, 2020, just days before COVID-19 would turn New York City’s hospitals into something approaching a war zone. If the doctors knew what was coming, they didn’t let on. They were cool and collected as they put Blechner, then 67, through a sonogram and a CT scan. But the pictures turned her world upside down.

Advertisement

“They said I have a tumor on my pancreas. And I said, ‘No, it can’t be. This can’t be happening to me. I don’t drink. I don’t smoke. I’m leading a healthy life.’”

After an anxious two days in the hospital, Blechner headed home and weighed her options. There weren’t many. Pancreatic cancer is notoriously unforgiving: Just 1 in 4 patients lives a year after their diagnosis. Just 1 in 10 makes it two years.

Blechner felt the numbers in the pit of her stomach as she, her husband and their three adult sons made calls and pored over the internet, deciding her next move. They settled on a path that would land Blechner in a fast-moving and often misunderstood realm of cancer research.

Messenger RNA, or mRNA, is a single-stranded molecule that delivers genetic information from DNA to direct the formation of proteins. It’s known to most people from high school science classes or for its use in COVID vaccines. But long before anyone had heard of COVID, mRNA was generating intense excitement in the cancer research community. BioNTech, the German company that designed the COVID vaccine for Pfizer, adapted that vaccine from a platform it had been using to develop cancer treatments for nearly a decade.

The mRNA-based COVID vaccines produced by Pfizer and Moderna helped blunt the impact of the pandemic but also sparked political backlash that, in the past year, has threatened to slow or derail dozens of potential cancer treatments. Now, after a tumultuous 12 months, there are signs that the mRNA train is still on track.

“It’s exciting,” said Elizabeth Jaffee, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. “There’s been a number of successes in early-stage, positive trials.”

Dr. Catherine Wu, a professor of medicine at Dana Farber Cancer Institute and Harvard Medical School, says the recent stretch of positive real-world results helped drive the recent announcement by the National Cancer Institute that it would help raise $200 million specifically for novel cancer vaccines.

“We’re getting a lot of support from NCI in terms of developing and promoting cancer vaccines, and mRNA vaccines are a major part of that portfolio,” she said.

An unforgiving enemy

To guide her treatment, Blechner turned to doctors at Memorial Sloan Kettering Cancer Center, including Dr. Vinod Balachandran, director of MSK’s Olayan Center for Cancer Vaccines.

It’s more challenging to make a vaccine against cancer than it is to create a vaccine against a virus or bacteria, Balachandran says. “That’s because our body’s immune systems are hard-wired to recognize viruses and pathogens as foreign, so a vaccine is teaching our body to do something it already wants to do. In contrast, cancer is ourselves. It’s derived from our own tissues.”

Much of Balachandran’s work the past two decades has focused on pancreatic tumors because the disease is such a tough nut to crack. “It’s a cancer where nothing had really worked,” he said.

When Blechner arrived at MSK, he was just launching a trial of an experimental mRNA-based vaccine against pancreatic cancer, in combination with standard immunotherapy and chemotherapy. He felt like a successful vaccine would also have the potential for wider application. “If we could break through and crack the toughest one, it could unlock how to crack the other [types of cancer], because it would provide a blueprint.”

To develop the vaccine, he began by studying “super-survivors”: the fewer than 10% of pancreatic cancer patients who live more than five years from the time of diagnosis. He found that their immune systems were especially good at spontaneously recognizing cancer cells as foreign. In fact, Balachandran says, these patients had about 12 times as many T-cells - a specialized type of immune cell - inside their tumors as average patients. The same T cells were circulating for more than a decade, in some cases.

Balachandran also realized that these weren’t generic cancer-fighters. “These T cells were recognizing mutations,” he said, “but each person’s immune system was recognizing their cancer as foreign in a very specific way. To replicate this would require us to teach each individual person’s immune system how to recognize their individual cancer. It would be an individualized vaccine. And we felt the best technology for rapid custom cancer vaccination was to use RNA.”

Taking a chance as a research volunteer

After Blechner signed on for the trial, the first step was surgery. She underwent what’s known as a Whipple procedure to remove the tumor in the head of her pancreas. In a lab at MSK, the tumor was preserved and sliced into fine pieces, each thinner than a human hair. In less than 72 hours, the package was en route to Germany, where technicians at BioNTech took steps to process the material into a clear liquid: a personalized vaccine, custom-made for Vita Sara Blechner.

A little more than two months after her diagnosis, the vaccine concoction from Germany arrived back in New York. By that time, she had been given a dose of an immune checkpoint inhibitor, an immunotherapy drug designed to make her immune cells more effective in fighting cancer. For weekly infusions of the vaccine, her husband, Simon, would drive Blechner from Oceanside to the MSK hospital on Manhattan’s East Side. It was the height of the COVID pandemic, so instead of running errands or visiting friends after dropping her off, he would drive through empty streets and wait back home on Long Island. Blechner would lie in a hospital bed for eight hours while the vaccine coursed through her body, until Simon returned to pick her up.

After nine weeks, she was done and ready for the next step in her treatment: chemotherapy. But chemo was a fiasco. Blechner suffered mightily, with side effects so severe that doctors had to halt treatment. “I got very sick,” she recalled.

“I only had three sessions before they had to stop, and I was in and out of the hospital three or four times. I was down to 90 pounds. I had no appetite. I was constantly nauseous, and my liver was damaged,” she said. “My doctor said to me she never thought she’d see me again.”

By the time she felt strong enough to try again, her doctors felt it would be unsafe to resume. She hoped that stopping early wouldn’t make a difference. But she would have to wait and see.

She tells this story more than six years later: Blechner not only survived longer than anyone expected, she’s still doing well and showing no sign of cancer.

And she’s no singular exception. Of 16 patients in Balachandran’s trial, eight showed a dramatic immune response to the mRNA-based vaccine. Seven of the eight are alive and well six years after the trial began, a finding that was to be presented Monday at the American Association of Cancer Research meeting in San Diego.

“It’s exciting,” Balachandran said. “The implication is that you can make a very strong immune response against the toughest of cancers, and it can last for this long. So if you could do it here, you could potentially do it in many other cancers.”

Although a study with 16 patients is far from definitive, a larger multisite trial has been underway for a year.

The announcement comes on the heels of other encouraging news for pancreatic cancer patients. Earlier this month, the New York Times published an interview with former U.S. Sen. Ben Sasse of Nebraska, who has been battling advanced pancreatic cancer and told the Times he’s been taking an experimental drug that caused his tumors to shrink, albeit with some painful side effects. Last week, Revolution Medicines, the California-based biotech company running the phase 3 trial that Sasse is part of, said in a news release that for patients whose cancer had spread, the drug nearly doubled survival time to 13.2 months, compared with 6.7 months among participants who didn’t get the drug. Revolution also said it will seek approval from the U.S. Food and Drug Administration for the drug, called daraxonrasib.

A promising technology under fire

Although much smaller than the Revolution study, the MSK trial stands as proof of concept for the promise of mRNA-based vaccines. The field has been a source of great excitement in recent years. But it also faced backlash in the wake of the pandemic and public concerns over COVID vaccines, even as most experts say major safety concerns around the latter are unfounded.

For cancer researchers, an early warning sign appeared in March 2025, when scientists reported that the acting director of the National Institutes of Health, Dr. Matthew Memoli, had sent a letter asking that all grants, collaborations or contracts involving mRNA be flagged.

For some, the low point came in May, when the White House proposed an unprecedented cut of more than 40% to funding for the National Cancer Institute. Twenty-six days later, in an apparently unrelated move, the U.S. Department of Health and Human Services canceled a $590 million deal with Moderna to develop an mRNA-based vaccine against emerging pandemic influenza. In August, HHS followed up by announcing it would no longer fund mRNA research through the Biomedical Advanced Research and Development Authority. The latter move involved the cancellation of 22 separate contracts.

More recently, the FDA canceled its review of Moderna’s mRNA-based flu vaccine, while criticizing the design of the company’s clinical trial, but the agency reversed its decision a week later after fierce criticism.

FDA Commissioner Dr. Marty Makary has said the agency bears no animus toward mRNA and that it terminated contracts last year solely to save taxpayer money. “The companies that made mRNA vaccines made over $50 billion. They can fund their own research,” Makary said at a news conference in February.

Still, many researchers who once saw a bright future felt their faith shaken. “The external threats are real,” Wu said. “It forced us to really step back and think. I wouldn’t be genuine if I said we weren’t all concerned.”

Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute, says mistrust of mRNA vaccines since the pandemic has at times made it harder to recruit people into his clinical trials.

“Most people don’t have significant concerns, but some are reluctant,” Sullivan said. “The skepticism over vaccines in general is a little bit lessened around cancer vaccines, but not totally, and some people are resistant to the concept, even when they’re fighting cancer.”

One technology, many paths

Sullivan is an investigator on multiple studies with mRNA vaccines, including a large-scale trial run by drugmakers Moderna and Merck, testing an mRNA-based therapy in combination with Keytruda, an immunotherapy drug, as a treatment for melanoma. In January, the companies announced that the combination cut the death rate for participants in their study by 49% over five years. A larger phase 3 trial is underway, and the companies are also testing the therapy against non-small cell lung cancer, bladder cancer and renal cell carcinoma.

Like the vaccine that helped Blechner, Merck and Moderna’s melanoma treatment is personalized, meaning an individual patient’s tumor cells are used to engineer a highly specific immune response. Another approach involves what are called generalized or off-the-shelf vaccines, that are not tailored to each individual patient. BioNTech and the Moderna/Merck collaboration are both working on approaches that use mRNA to encode and deliver a predefined set of antigens - immune targets - that are typically shared across patients with a given tumor type in hopes of stimulating the immune system into a more aggressive response.

Dr. Elias Sayour, a pediatric oncologist and researcher at the University of Florida, has gone a step further in the “generic” direction, testing mRNA vaccines that don’t code for any specific antigen at all. In a study published last year in the journal Nature Biomedical Engineering, Sayour treated mice with a generalized vaccine, using mRNA to stimulate production of a protein called PD-L1, making their tumors more susceptible to immunotherapy. It worked.

“We’ve discovered that mRNA doesn’t need to be specific, to reprogram the immune response,” Sayour said.

“We’re trying to create a new paradigm,” he added. “It takes weeks to create a personalized vaccine. The idea of universalization is to wake up the immune system more rapidly.”

He says the two approaches could, in theory, complement each other: A newly diagnosed patient might receive an off-the-shelf vaccine to ramp up their immune system and a personalized vaccine later in their course of treatment.

A recent illustration of the “universal vaccine” approach came in a study led by Drs. Adam Grippin and Steven Lin of MD Anderson Cancer Center. They reviewed records of more than a thousand cancer patients treated with immune checkpoint inhibitors and found that getting an mRNA-based COVID vaccine was linked to a significantly better response to cancer drugs.

Patients with small cell lung cancer who had gotten a COVID shot within 100 days of starting treatment lived nearly twice as long as those who hadn’t. For those with melanoma, researchers couldn’t calculate the difference in survival time because so many of the patients who had gotten a COVID vaccine were still alive.

“Most people think about vaccines as a laser-guided missile,” said Grippin, who before coming to MD Anderson was a graduate student in Sayour’s lab. “That may be true, but our research suggests that mRNA also acts as a siren call to the overall immune system.”

Grippin is now collaborating with Sayour to plan a trial in which patients will be intentionally given a COVID vaccine prior to starting cancer treatment.

Money flowing but still tight

Dr. Robert Vonderheide, director of the Abramson Cancer Center at the University of Pennsylvania and president-elect of the American Association for Cancer Research, says that the field took hits last year but that public pressure turned the tide. “The entire country has been asking, ‘How valuable is cancer research to our society?’ And what we heard from the public and our patients is, it’s super-important.”

Federal research grants have started to flow again, after major interruptions over the past several months. Last week, NCI Director Anthony Letai told the Cancer Letter podcast that 22 competitive grants were awarded March 17 and another 167 awarded over the next three-plus weeks.

Still, there are scars. One of Sayour’s proposals – to test an mRNA-based vaccine against a rare form of childhood brain tumor – was approved by the NCI last year. But after the agency reduced by nearly half its total number of awards, he says the money never arrived.

He says he expects the work to go forward, eventually, but it will take time to find the funding. “As you can imagine, I’ve shifted my approach to finances,” Sayour said. “The reality is, there’s a lot of dependency on the federal government, and if you put all your faith in one stock, you could go under pretty quickly.”

While federal funding remains tight, the most prominent mRNA cancer vaccines have attracted industry support and are not reliant on grants. Moderna says it expects to release data from the phase 3 melanoma trial this year. Genentech and BioNTech are sponsoring the global multisite test of the vaccine that Blechner received, with Balachandran leading efforts at MSK.

“You need a platform that is fast and potent, flexible and scalable,” Balachandran said. “There are other ways to generate immune responses, but the RNA platform at the moment seems to be superior.”

Although none of the cancer vaccine platforms has inspired major safety concerns, Jaffee notes that thanks to the COVID experience, mRNA vaccines have a particularly extensive record. “We’ve seen two-billion-plus injections, and there’s no data to show that mRNA vaccines cause any serious problems,” she said.

Vita Sara Blechner is no longer waiting for the other shoe to drop. “I guess once I hit my fifth year [cancer-free], it really sank in that I’m doing well. I said, ‘I beat the odds.’ Now I’m grateful every day,” she said. “I’m really looking forward to my sons getting married. I’m looking forward to the holidays, since I have the strength to do the work and have everyone over. We just had a family event a week ago, and we danced and ate and had a great time. Every day is wonderful.”

Weather Information

FEELS LIKE
RADAR TRAFFIC
Sponsored by
X
Make WLKY a preferred source on Google